Chembio Diagnostics (CEMI) announced that it has received a CE mark for its diagnostic test developed in collaboration with AstraZeneca (AZN). Chembio and AstraZeneca have collaborated to develop a quantitative diagnostic test to detect an undisclosed biomarker, using Chembio’s patented DPP platform. The CE marked DPP System, which includes the new DPP(R) test and DPP Micro Reader, provides quantitative results in ten minutes from a small drop of fingertip or venous blood. In December 2017, Chembio announced an 18-month agreement with AstraZeneca, under which Chembio will receive up to $2.9M in funding from AstraZeneca, subject to satisfying certain milestones, to develop a quantitative reader-based point-of-care test utilizing Chembio’s patented DPP platform. The DPP platform is the same technology used for Chembio’s DPP HIV 1/2 Assay, which is FDA-approved, CLIA Waived, CE marked, and WHO pre-qualified.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.